Drug Trial Radar · NCT07597629
A Clinical Study of SYS6023 Combination Therapy for Advanced Breast Cancer
Last checked: Nov 19, 2026Latest source record: Jun 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
36
Planned (sponsor's estimate)
Start
May 25, 2026
Primary completion
Nov 30, 2027
Study completion May 30, 2029
Sponsor
- Lead sponsor
- CSPC Megalith Biopharmaceutical Co.,Ltd.Industry
- Sponsor type
- Industry
- First posted
- May 19, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is an open-label, multicenter Phase II clinical study conducted in subjects with advanced breast cancer.
Conditions
- Advanced Breast Cancer
Interventions
SYS6023Drug
SYS6023 is a novel antibody-drug conjugate (ADC) targeting HER3, administered via intravenous infusion.
KN026Drug
KN026 is an antibody targeting HER2, administered via intravenous infusion.
Primary outcomes
What the sponsor says the trial is designed to measure.
- The incidence of dose-limiting toxicity (DLT)Time frame: At the end of Cycle 1 (each cycle is 21 days).
- Frequency and severity of AEs and SAEs (according to NCI-CTCAE 6.0);Time frame: Baseline up to 28 days post last dose, Up to approximately 3 years
- Recommended Phase 2 Dose(RP2D)Time frame: Up to approximately 3 years
- Objective Response Rate (ORR)Time frame: Up to approximately 3 years
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Affiliated Tumor Hospital of Harbin
Harbin, Heilonjiang, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.